Previous 10 | Next 10 |
2023-11-01 13:38:15 ET Gainers: Patriot Transportation Holding ( PATI ) +103% . Aldeyra Therapeutics ( ALDX ) +50% . Davis Commodities Ltd. ( DTCK ) +33% . TG Therapeutics ( TGTX ) +32% . Silence Therapeutics ( SLN ) +31% . S...
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced an...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will partic...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management...
2023-08-16 14:47:43 ET More on Silence Therapeutics Silence Therapeutics: No Reason For It To Fall So Much Silence Therapeutics to receive another $4M payment from Hansoh Pharma collaboration Silence Therapeutics overweight at Morgan Stanley on RNAi platform ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results fo...
2023-07-14 19:15:54 ET Summary SLN has fallen 65% after my last article. They produced good early data, they have decent cash, and there's no negative news. I can identify no reason for the stock to have declined so much. After I called out Silence Therapeutics ( S...
2023-07-11 07:52:18 ET Silence Therapeutics ( NASDAQ: SLN ) to receive a $4M cash payment from Hansoh Pharmaceutical Group Company following the achievement of two undisclosed preclinical milestones. M payment is the second and third research milestone payments achieved under the ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will p...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...